Urinary cannabinoid detection times after controlled oral administration of Δ9-tetrahydrocannabinol to humans

Clinical Chemistry

Volumn 49, Issue 7, 2003, Pages 1114-1124

  Gustafson, Richard A ^a   Levine, Barry ^b   Stout, Peter R ^c   Klette, Kevin L ^d   George, M P ^e   Moolchan, Eric T ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b OFFICE OF THE CHIEF MEDICAL EXAMINER   (United States)

^c Aegis   (United States)

^d Navy Drug Screening Laboratory   (United States)

^e QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; DRONABINOL; DRUG METABOLITE;

ACCURACY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG EXCRETION; DRUG URINE LEVEL; EVALUATION; FEMALE; FOOD ANALYSIS; FOOD COMPOSITION; GAS CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MALE; MASS SPECTROMETRY; PRODUCTIVITY; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

ADMINISTRATION, ORAL; ADULT; CANNABIS; DOUBLE-BLIND METHOD; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; IMMUNOASSAY; MALE; PLANT OILS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE DETECTION; TETRAHYDROCANNABINOL; TIME FACTORS;

CANNABIS; CANNABIS SATIVA;

EID: 0038037722     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.7.1114     Document Type: Article

References (34)

1. Halldin MM, Widman M, Agurell S, Hollister LE, Kanter SL. Acidic metabolites of delta-1-tetrahydrocannabinol excreted in the urine of man. In: Agurell S, Dewey WL, Willette RE, eds. The cannabinoids: chemical, pharmacologic, and therapeutic aspects. New York: Academic Press, 1984:211-8.
2. McBurney LJ, Bobbie BA, Sepp LA. GC/MS and Emit analyses for delta-9-tetrahydrocannabinol metabolites in plasma and urine of human subjects. J Anal Toxicol 1986;10:56-64.
3. Johansson E, Halldin MM. Urinary excretion half-life of delta1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J Anal Toxicol 1989;13:218-23.
4. Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 1992;16:228-35.
5. 9-tetrahydrocannabinol in humans after single smoked doses of marijuana. J Anal Toxicol 1996;20:441-52.
6. Huestis MA, Cone EJ. Urinary excretion half-life of 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans. Ther Drug Monit 1998;20:570-6.
7. Perez-Reyes M, Lipton MA, Timmons MC, wall ME, Brine DR, Davis KH. Pharmacology of orally administered delta-9-tetrahydrocannabinol. Clin Pharmacol Ther 1973;14:48-55.
8. Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983;34:352-63.
9. Law B, Mason PA, Moffat AC, Gleadle RI, King LJ. Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol 1984;36:289-94.
10. Sadler BM, Wall ME, Perez-Reyes M. The pharmacokinetics of delta-9-tetrahydrocannabinol after simultaneous intravenous and oral administration. In: Agurell S, Dewey WL, Willette RE, eds. The cannabinoids: chemical, pharmacologic, and therapeutic aspects. New York: Academic Press, 1984:227-38.
11. Cone EJ, Johnson RE, Paul BD, Mell LD, Mitchell J. Marijuana-laced brownies: behavioral effects, physiologic effects, and urinalysis in humans following ingestion. J Anal Toxicol 1988;12:169-75.
12. Lehmann T, Sager F, Brenneisen R. Excretion of cannabinoids in urine after ingestion of cannabis seed oil. J Anal Toxicol 1997;21:373-5.
13. Alt A, Reinhardt G. Positive cannabis results in urine and blood samples after consumption of hemp food products. J Anal Toxicol 1998;22:80-1.
14. Bosy TZ, Cole KA. Consumption and quantitation of delta-9-tetrahydrocannabinol in commercially available hemp seed oil products. J Anal Toxicol 2000;24:562-6.
15. Fortner N, Fogerson R, Lindman D, Iversen T, Armbruster D. Marijuana-positive urine test resets from consumption of hemp seeds in food products. J Anal Toxicol 1997;21:476-81.
16. Struempler RE, Nelson G, Urry FM. A positive cannabinoids workplace drug test following the ingestion of commercially available hemp seed oil. J Anal Toxicol 1997;21:283-5.
17. Callaway JC, Weeks RA, Raymon LP, Walls HC, Hearn WL. A positive THC urinalysis from hemp (Cannabis) seed oil. J Anal Toxicol 1997;21:319-20.
18. 9-tetrahydrocanabinol carboxylic acid. J Anal Toxicol 1997;21:482-5.
19. Leson G, Pless P, Grotenhermen F, Kalant H, ElSohly MA. Evaluating the impact of hemp food consumption on workplace drug tests. J Anal Toxicol 2001;25:691-8.
20. Interpretation of listing of "tetrahydrocannabinol". in Schedule I [Interpretive Rule]. Fed Regist 2001;195:51530-44.
21. Mechoulam R. Recent advances in cannabinoid research. Forsch Komplementarmed 1999;6:16-20.
22. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs 2000;60:1303-14.
23. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 2001;178:107-15.
24. Stout PR, Horn CK, Klette KL. Solid-phase extraction and GC-MS analysis of THC-COOH method optimized for a high-throughput forensic drug-testing laboratory. J Anal Toxicol 2001;25:550-4.
25. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hellister LE, Gillespie HK. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980;28:409-16.
26. Watanabe K, Narimatsu S, Matsunaga T, Yamamoto I, Yoshimura H. A cytochrome P450 isozyme having aldehyde oxygenase activity plays a major role in metabolizing cannabinoids by mouse hepatic microsomes. Biochem Pharmacol 1993;46:405-11.
27. Williams PL, Moffat AC. Identification in human urine of delta-9-tetrahydrocannabinol-11-oic glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 1980;32:445-8.
28. Liu RH, Goldburger BA. Handbook of workplace drug testing, 1st ed. Washington, DC: AACC Press, 1995:67-129.
29. Lyons TP, Okano CK, Kuhnle JA, Bruins MR, Darwin WD, Moolchan ET, et al. A comparison of Roche Kinetic Interactions of Microparticles in Solution (KIMS) assay for cannabinoids and GC-MS analysis for 11-nor-carboxy-delta-9-tetrahydrocannabinol. J Anal Toxicol 2001;25:559-64.
30. Huestis MA, Mitchell JM, Cone EJ. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol 1995;19:443-9.
31. Irving J, Leeb B, Foltz RL, Cook CE, Bursey JT, Willette RE. Evaluation of immunoassays for cannabinoids in urine. J Anal Toxicol 1984;8:192-6.
32. Huestis MA, Mitchell JM, Cone EJ. Lowering the federally mandated cannabinoid immunoassay cutoff increases true-positive results. Clin Chem 1994;40:729-33.
33. ElSohly MA, deWit H, Wachtel SR, Feng S, Murphy TP. Delta-9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol 2001;25:565-71.
34. Foltz RL. Analysis of urine specimens for cannabinoids to distinguish the ingestion of marinol from smoked THC. Calif Assoc Toxicol Proc 1996;November:28-31.